5 Key Takeaways

• 1

  Cabozantinib may prolong progression-free survival in patients with advanced neuroendocrine tumors, according to a phase III trial.

• 2

  In the extrapancreatic cohort, median progression-free survival was 8.4 months with cabozantinib versus 3.9 months with placebo.

• 3

  In the pancreatic cohort, cabozantinib achieved a median progression-free survival of 13.8 months compared to 4.4 months with placebo.

• 4

  Grade 3 or higher treatment-related adverse events occurred in 62% to 65% of cabozantinib patients compared to 23% to 27% in the placebo group.

• 5

  The trial was terminated early due to significant efficacy signals, highlighting the need for further research on treatment strategies.